Atara Biotherapeutics Inc
ATRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$72.89M
Close$
$-2.33
127.4% downside
Current Fair Value
127.4% downsideOvervalued by 127.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $72.89 Million |
|---|---|
| Enterprise Value | $80.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.61 |
| Beta | 0.09 |
| Outstanding Shares | 15,033,000 |
Return
| Return on Equity | 45.11% |
|---|---|
| Return on Assets | -79.38% |
| Return on Invested Capital | -107.89% |
Valuation & Multiples
| P/E Ratio | -6.86 |
|---|---|
| PEG | 2.27 |
| Price to Sales | - |
| Price to Book Ratio | -2.84 |
| Enterprise Value to Revenue | 29.31 |
| Enterprise Value to EBIT | -5.25 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | -0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$550,000
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$750,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 2000% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.80%▼ 17.41% |
|---|---|
| Total Invested | $1.30M▼ 89.30% |
| Investors Holding | 8▼ 26.00% |
ESG Score
No data
About Atara Biotherapeutics Inc
CEO: Pascal Touchon